CSIMarket
 

Lixte Biotechnology Holdings Inc   (NASDAQ: LIXT)

Lixte Biotechnology Holdings Inc 's

Competitiveness




 

LIXT Sales vs. its Competitors Q2 2026



Comparing the current results to its competitors, Lixte Biotechnology Holdings Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 23.5 %, recorded in the same quarter.

• List of LIXT Competitors





Revenue Growth Comparisons




Net Income Comparison


Lixte Biotechnology Holdings Inc , faster than the decline experienced by the competitors recorded a net loss, as well as most of its competitors.

<<  LIXT Stock Performance Comparisons


Lixte Biotechnology Holdings Inc 's Comment on Competition and Industry Peers


The company operates in the life sciences industry, which is highly competitive and rapidly evolving technologically. It faces competition from major pharmaceutical companies, specialized biotechnology and life sciences firms in the United States and internationally, as well as from universities and other research institutions. Many competitors possess greater financial, technical, and marketing resources. Mergers and acquisitions may further concentrate resources among competitors. Competitors may develop more effective processes or products, obtain patent protection or regulatory approval before the company, and potentially render the company's product candidates obsolete or non-competitive. Competition also exists in acquiring technology from research institutions, with no assurance that others will not develop superior technologies that could adversely affect the company's business.



*Market share is calculated based on total revenue.





Publicly Traded Peers of Lixte Biotechnology Holdings Inc




Inhibitor Therapeutics Inc
Share Performance



0.00%
This Quarter



Inhibitor Therapeutics Inc
Profile

Inhibitor Therapeutics Inc's business model focuses on developing and commercializing innovative inhibitors for targeted therapies.

More about Inhibitor Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 15.043 mill. $ - mill. $ -3.308 mill.


Decoy Therapeutics Inc
Share Performance



+2.66%
30 Days



Decoy Therapeutics Inc
Profile

Decoy Therapeutics Inc. develops peptide conjugate therapeutics utilizing artificial intelligence and machine learning technologies.

More about Decoy Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1.644 mill. $ 0.228 mill. $ -14.450 mill.


Phio Pharmaceuticals Corp
Share Performance



-7.34%
This Year



Phio Pharmaceuticals Corp
Profile

Phio Pharmaceuticals Corp's business model revolves around developing and commercializing innovative RNA-based therapeutics to treat various diseases and improve patient outcomes.

More about Phio Pharmaceuticals Corp's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 11.733 mill. $ - mill. $ -12.904 mill.


Bolt Biotherapeutics Inc
Share Performance



-38.17%
This Year



Bolt Biotherapeutics Inc
Profile

Bolt Biotherapeutics Inc's business model focuses on developing novel immunotherapies for the treatment of cancer.

More about Bolt Biotherapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 6.052 mill. $ 4.700 mill. $ -28.739 mill.


Nextcure Inc
Share Performance



-61.75%
This Year



Nextcure Inc
Profile

NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.

More about Nextcure Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 26.973 mill. $ - mill. $ -42.748 mill.

46 more competitors available

Sign in to see all competitors

Sources: Lixte Biotechnology Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Lixte Biotechnology Holdings Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.